News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Mesoblast Limited In Strong Cash Position At End Of Financial Year
July 30, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Melbourne, July 30, 2009 (ABN Newswire) - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its cash position at 30 June 2009 was A$16.5 million.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Australia
MORE ON THIS TOPIC
China
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
September 24, 2026
·
1 min read
·
Tristan Manalac
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
September 23, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
September 21, 2026
·
2 min read
·
Nick Paul Taylor
China
China plans to transform biotech sector into $522B powerhouse by 2030
September 18, 2026
·
2 min read
·
Annalee Armstrong
